What does TB-500 do?

Your body produces a protein called thymosin beta-4 (Tβ4) in nearly every cell. It's one of the most abundant intracellular peptides you have, and its main job is regulating how your cells build and reorganise their internal scaffolding (a process called actin polymerisation).

When you get injured, thymosin beta-4 floods the area and does three key things: it tells repair cells — fibroblasts, stem cells, endothelial cells — to migrate to the injury site; it reduces inflammation by dialling down NF-κB signalling; and it reduces scar tissue formation by lowering TGF-β1. TB-500 is a synthetic fragment of this protein that aims to replicate these effects.

The result, at least in animal studies: faster wound healing, less fibrosis, better tendon and muscle repair, and improved recovery from cardiac injury.

Who uses it?

• Athletes with injuries — rotator cuff, Achilles tendon, hamstring tears, chronic joint inflammation
• Post-surgical recovery — used off-label to accelerate tissue healing
• Older athletes — dealing with injury sites that never fully healed
• Often stacked with BPC-157 — complementary mechanisms for comprehensive repair

What to know before trying

Injection only: Unlike BPC-157, TB-500 doesn't have a viable oral route. It's injected subcutaneously — usually in the abdomen or thigh — using insulin syringes.

Loading and maintenance: Most community protocols start with a loading phase (2–5 mg twice weekly for 4–6 weeks) followed by a lower maintenance dose (2–5 mg monthly). These are not validated human protocols.

Storage: Lyophilised TB-500 should be stored at -20°C before reconstitution. After reconstitution with bacteriostatic water, refrigerate and use within 28 days. Do not freeze once reconstituted.

Frequently Asked Questions

How it works in your body

TB-500 binds G-actin (monomeric actin), regulating the pool available for building cell scaffolding. This affects cell shape, migration speed, and division rate. The downstream effect is that repair cells — endothelial cells, fibroblasts, stem cells — migrate faster to injury sites.

It also downregulates NF-κB pathway activation, reducing production of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6). And it reduces TGF-β1 expression, which is the main driver of scar tissue formation — particularly relevant for cardiac and liver fibrosis.

Animal vs human evidence

• Thymosin beta-4 (full protein): Phase II clinical trials for cardiac repair after heart attack (METRO trial) and chronic wound healing. Showed safety and modest functional improvement.
• TB-500 (fragment): Animal studies show consistent effects for tendon healing, muscle repair, and scar reduction. The fragment is assumed to carry the key active region, but this has not been validated in humans.
• The extrapolation gap: Using human data from the full 43-amino acid protein to justify the 7-amino acid fragment is common in the peptide community but not pharmacologically validated.

Sourcing and quality

TB-500 is imported as a research chemical, primarily from manufacturers in China and Eastern Europe. Quality varies widely. Look for suppliers who provide batch-specific certificates of analysis with HPLC purity ≥98%. Store lyophilised powder at -20°C; reconstituted peptide at 2–8°C.

Side effects & safety

TB-500's safety profile is understudied in humans. Here's what's known and what's theoretical:

• Injection site reactions — redness, swelling, or tenderness. The most common reported effect. Usually resolves within hours.
• Fatigue — some users report feeling tired for 24–48 hours after injection, particularly during the loading phase.
• Nausea — mild and usually transient, more common in early use.
• Cell migration concern — TB-500 promotes cell proliferation and migration. While this accelerates healing, it's theoretically counterproductive if undetected tumours are present. People with active cancer or significant cancer risk should avoid it.
• Immune modulation — the anti-inflammatory effects may theoretically blunt appropriate immune responses during active infections.
• Injection safety — sterile technique is non-negotiable. Injection site infections from non-sterile practice are a real and immediate risk.

Who should avoid it: People with active cancer or a history of cancer, those with active infections, pregnant or breastfeeding women, and anyone on immunosuppressant therapy.

Related